Gilead is frustrated because Stribild, a once-a-day pill that was approved last summer, contains four Gilead compounds, but only two of which have new active moieties.
In its petition, the biotech notes that the FDA has denied exclusivity to 10 fixed-dose combination drugs containing both new and previously approved active moieties for nearly 20 years.